Leonid Timashev
Stock Analyst at RBC Capital
(4.25)
# 430
Out of 5,113 analysts
147
Total ratings
56.49%
Success rate
13.61%
Average return
Main Sectors:
Stocks Rated by Leonid Timashev
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMPS COMPASS Pathways | Maintains: Outperform | $16 → $21 | $7.17 | +192.89% | 5 | Jan 23, 2026 | |
| IDYA IDEAYA Biosciences | Maintains: Outperform | $41 → $45 | $34.80 | +29.31% | 4 | Jan 21, 2026 | |
| CYTK Cytokinetics | Reiterates: Outperform | $95 | $63.41 | +49.82% | 6 | Jan 21, 2026 | |
| CGON CG Oncology | Maintains: Outperform | $61 → $73 | $53.81 | +35.66% | 3 | Jan 21, 2026 | |
| AXSM Axsome Therapeutics | Maintains: Outperform | $212 → $219 | $185.96 | +17.77% | 15 | Jan 21, 2026 | |
| NAMS NewAmsterdam Pharma Company | Maintains: Outperform | $44 → $47 | $33.32 | +41.06% | 9 | Jan 21, 2026 | |
| NUVB Nuvation Bio | Maintains: Outperform | $9 → $12 | $5.59 | +114.67% | 4 | Jan 21, 2026 | |
| CRMD CorMedix | Maintains: Outperform | $22 → $13 | $7.27 | +78.82% | 3 | Jan 21, 2026 | |
| RVMD Revolution Medicines | Maintains: Outperform | $77 → $140 | $117.63 | +19.02% | 2 | Jan 21, 2026 | |
| INSM Insmed | Maintains: Outperform | $197 → $200 | $156.21 | +28.03% | 8 | Jan 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $9 → $22 | $13.51 | +62.84% | 14 | Jan 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $66 | $19.01 | +247.19% | 15 | Jan 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $5 | $1.63 | +206.75% | 7 | Dec 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $6 → $13 | $10.18 | +27.70% | 10 | Nov 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $395 → $408 | $339.32 | +20.24% | 5 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $155 → $194 | $168.71 | +14.99% | 3 | Nov 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $5 → $4 | $1.57 | +154.78% | 1 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $49 → $50 | $28.61 | +74.76% | 15 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $19 | $12.78 | +48.67% | 3 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $27 → $11 | $6.95 | +58.27% | 2 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $45 → $47 | $33.61 | +39.84% | 5 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $45 | $44.27 | +1.65% | 2 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $13 | $6.38 | +103.76% | 2 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $5 | $3.61 | +38.50% | 1 | Jun 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $16 | $2.71 | +490.41% | 1 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3 | $0.95 | +215.79% | 1 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $70 | $101.99 | -31.37% | 1 | Jan 23, 2025 |
COMPASS Pathways
Jan 23, 2026
Maintains: Outperform
Price Target: $16 → $21
Current: $7.17
Upside: +192.89%
IDEAYA Biosciences
Jan 21, 2026
Maintains: Outperform
Price Target: $41 → $45
Current: $34.80
Upside: +29.31%
Cytokinetics
Jan 21, 2026
Reiterates: Outperform
Price Target: $95
Current: $63.41
Upside: +49.82%
CG Oncology
Jan 21, 2026
Maintains: Outperform
Price Target: $61 → $73
Current: $53.81
Upside: +35.66%
Axsome Therapeutics
Jan 21, 2026
Maintains: Outperform
Price Target: $212 → $219
Current: $185.96
Upside: +17.77%
NewAmsterdam Pharma Company
Jan 21, 2026
Maintains: Outperform
Price Target: $44 → $47
Current: $33.32
Upside: +41.06%
Nuvation Bio
Jan 21, 2026
Maintains: Outperform
Price Target: $9 → $12
Current: $5.59
Upside: +114.67%
CorMedix
Jan 21, 2026
Maintains: Outperform
Price Target: $22 → $13
Current: $7.27
Upside: +78.82%
Revolution Medicines
Jan 21, 2026
Maintains: Outperform
Price Target: $77 → $140
Current: $117.63
Upside: +19.02%
Insmed
Jan 21, 2026
Maintains: Outperform
Price Target: $197 → $200
Current: $156.21
Upside: +28.03%
Jan 21, 2026
Upgrades: Outperform
Price Target: $9 → $22
Current: $13.51
Upside: +62.84%
Jan 20, 2026
Maintains: Outperform
Price Target: $66
Current: $19.01
Upside: +247.19%
Dec 19, 2025
Maintains: Outperform
Price Target: $8 → $5
Current: $1.63
Upside: +206.75%
Nov 20, 2025
Upgrades: Outperform
Price Target: $6 → $13
Current: $10.18
Upside: +27.70%
Nov 18, 2025
Maintains: Outperform
Price Target: $395 → $408
Current: $339.32
Upside: +20.24%
Nov 17, 2025
Maintains: Outperform
Price Target: $155 → $194
Current: $168.71
Upside: +14.99%
Nov 11, 2025
Maintains: Sector Perform
Price Target: $5 → $4
Current: $1.57
Upside: +154.78%
Nov 7, 2025
Maintains: Outperform
Price Target: $49 → $50
Current: $28.61
Upside: +74.76%
Nov 6, 2025
Maintains: Outperform
Price Target: $18 → $19
Current: $12.78
Upside: +48.67%
Oct 31, 2025
Downgrades: Sector Perform
Price Target: $27 → $11
Current: $6.95
Upside: +58.27%
Oct 23, 2025
Maintains: Outperform
Price Target: $45 → $47
Current: $33.61
Upside: +39.84%
Oct 21, 2025
Reiterates: Sector Perform
Price Target: $45
Current: $44.27
Upside: +1.65%
Aug 8, 2025
Maintains: Outperform
Price Target: $12 → $13
Current: $6.38
Upside: +103.76%
Jun 20, 2025
Maintains: Outperform
Price Target: $8 → $5
Current: $3.61
Upside: +38.50%
Jun 3, 2025
Maintains: Outperform
Price Target: $15 → $16
Current: $2.71
Upside: +490.41%
Mar 19, 2025
Maintains: Buy
Price Target: $3
Current: $0.95
Upside: +215.79%
Jan 23, 2025
Reiterates: Sector Perform
Price Target: $70
Current: $101.99
Upside: -31.37%